Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Neuropharmacology. 2012 May 10;63(4):642–652. doi: 10.1016/j.neuropharm.2012.04.033

Figure 2. Effect of VEGF on phospho-CREB expression in the hippocampus.

Figure 2

(A) Time course western blot analysis of phospho-CREB expression in hippocampal homogenates at 0, 0.5 hr, 1 hr, 2 hr, and 4 hr after VEGF microinfusion. Levels of phospho-CREB in the hippocampus are increased 0.5 hr after VEGF microinfusion and persist for 4 hrs. One-way ANOVA, Bonferroni: * P<.05 vs. 0 hr. (B) Representative photomicrographs showing phospho-CREB expression in DMSO/PBS, DMSO/VEGF, SU5416/PBS, and SU5416/VEGF treated rats sacrificed 3 hrs later. DMSO or SU5416 was administered 30 minutes before treatment with PBS or VEGF. (C) Quantitative analysis of the inner dentate granule cell layer/SGZ, middle dentate granule cell layer, and outer regions of the dentate granule cell layer shows that VEGF increased phospho-CREB expression in the inner/SGZ and middle dentate granule cell layers. Pretreatment with the Flk-1 inhibitor SU5416 prevents VEGF-stimulation of CREB in these regions. Two-way ANOVA, Bonferroni: * P<.05 vs. DMSO/PBS controls. Error bars denote mean ± SEM